Arthroscopic Matrix-Encapsulated Autologous Chondrocyte Implantation: A Pilot Multicenter Investigation in Latin America. (December 2021)

• Record Type: Journal Article
• Authors: Villalobos, Enrique; Madrazo-Ibarra, Antonio; Martínez, Valentín; Olivos-Meza, Anell; Velasquillo, Cristina; Cortés González, Socorro; Izaguirre, Aldo; Ortega-Sánchez, Carmina; González, Ricardo; Parra-Cid, Carmen; Pérez-Jiménez, Francisco Javier; Ibarra, Clemente
• Is Part Of: Cartilage. Volume 13:Number 1(2022)Supplement
• Page Start: 1074S
• Page End: 1084S
• Publication Date: 2021-12
• Subjects: matrix-assisted autologous chondrocyte implantation -- T2-mapping -- biosecurity parameters -- AMECI -- multicenter study; Cartilage -- Periodicals; 616.7
• DOI: 10.1177/1947603520918630
• Languages: English
• ISSNs: 1947-6035

Abstract

Objective . To evaluate minimum biosecurity parameters (MBP) for arthroscopic matrix-encapsulated autologous chondrocyte implantation (AMECI) based on patients' clinical outcomes, magnetic resonance imaging (MRI) T2-mapping, Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, and International Cartilage Repair Society (ICRS) second-look arthroscopic evaluation, laying the basis for a future multicenter study. Design . Pilot clinical study. We analyzed the logistics to perform AMECI to treat focal chondral lesions in different hospitals following strict biosecurity parameters related to tissue and construct transportation, chondrocyte isolation, and cell expansion. Patient progress was analyzed with patient-reported outcome measures, MRI T2-mapping, MOCART, and ICRS arthroscopic second-look evaluation. Results . Thirty-five lesions in 30 patients treated in 7 different hospitals were evaluated. Cell viability before implantation was >90%. Cell viability in construct remnants was 87% ± 11% at 24 hours, 75% ± 17.1% at 48 hours, and 60% ± 8% at 72 hours after implantation. Mean final follow-up was 37 months (12-72 months). Patients showed statistically significant improvement in all clinical scores and MOCART evaluations. MRI T2-mapping evaluation showed significant decrease in relaxation time from 61.2 ± 14.3 to 42.9 ± 7.2 ms ( P < 0.05). Arthroscopic second-look evaluation showed grade II "near normal" tissue in 83% of patients. Two treatment failures were documented. Conclusions . It was feasible to perform AMECI in 7 different institutions in a large metropolitan area following our biosecurity measures without any implant-related complication. Treated patients showed improvement in clinical, MRI T2-mapping, and MOCART scores, as well as a low failure rate and a favorable ICRS arthroscopic evaluation at a mid-term follow-up. Level of Evidence . 2b.